Tivic Health announces 1-for-17 reverse stock split effective March 7, 2025 to regain Nasdaq compliance

Valion Bio, Inc.

Reverse split at 1:17 ratio; effective 12:01 a.m. ET on March 7, 2025.
Purpose: regain Nasdaq $1.00 minimum bid price after delisting notice received December 2024.
Hearing before Nasdaq Panel held Feb 18, 2025; company awaits decision but expects split to aid listing.
No fractional shares; any fractional interest rounded up to nearest whole share.
Trading symbol TIVC unchanged; new CUSIP 888705308.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.